Top

Published in:

01-07-2009 | Epidemiology

CHEK2 1100delC and male breast cancer in the Netherlands

Authors: Marijke Wasielewski, Michael A. den Bakker, Ans van den Ouweland, Marion E. Meijer-van Gelder, Henk Portengen, Jan G. M. Klijn, Hanne Meijers-Heijboer, John A. Foekens, Mieke Schutte

Published in: Breast Cancer Research and Treatment | Issue 2/2009

Abstract

Mutations in the breast cancer susceptibility genes BRCA1, BRCA2, and CHEK2 are known risk factors for female breast cancer. Mutations in BRCA1 and BRCA2 also are associated with male breast cancer (MBC). Similarly, it had been suggested in the original CHEK2 identification report that the CHEK2 1100delC mutation confers an increased risk for MBC. Here, we have evaluated the risk of CHEK2 1100delC for MBC by genotyping CHEK2 1100delC in 23 familial and 71 unselected Dutch MBC cases. None of the 23 familial MBC cases carried the CHEK2 1100delC mutation. In contrast, CHEK2 1100delC was present in 3 of the 71 (4.2%) unselected MBC cases, which was significantly more prevalent than the 1.1% Dutch population frequency assessed in 1,692 individuals (P = 0.05, OR = 4.1, 95% CI 1.2–14.3). Our data suggest that, in the Netherlands, CHEK2 1100delC is associated with an increased risk for MBC.

Weiss JR, Moysich KB, Swede H (2005) Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev 14:20–26. doi:10.1158/1055-9965.EPI-05-0414 PubMedCrossRef

Fentiman IS, Fourquet A, Hortobagyi GN (2006) Male breast cancer. Lancet 367:595–604. doi:10.1016/S0140-6736(06)68226-3 PubMedCrossRef

Nahleh Z, Girnius S (2006) Male breast cancer: a gender issue. Nat Clin Pract Oncol 3:428–437. doi:10.1038/ncponc0564 PubMedCrossRef

Meijers-Heijboer H, van den Ouweland A, Klijn J et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55–59. doi:10.1038/ng879 PubMedCrossRef

Vahteristo P, Bartkova J, Eerola H et al (2002) A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71:432–438. doi:10.1086/341943 PubMedCrossRef

Consortium CBCC-C (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74:1175–1182. doi:10.1086/421251 CrossRef

Choi DH, Cho DY, Lee MH et al (2008) The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation. Breast Cancer Res Treat. doi:10.1007/5105490079878z

Dufault MR, Betz B, Wappenschmidt B et al (2004) Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer 110:320–325. doi:10.1002/ijc.20073 PubMedCrossRef

Evans DG, Bulman M, Young K et al (2007) BRCA1/2 mutation analysis in male breast cancer families from North West England. Fam Cancer 7:113–117. doi:10.1007/s10689-007-9153-9 PubMedCrossRef

10.

Falchetti M, Lupi R, Rizzolo P et al (2008) BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat 110:161–167. doi:10.1007/s10549-007-9689-2 PubMedCrossRef

11.

Friedrichsen DM, Malone KE, Doody DR, Daling JR, Ostrander EA (2004) Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women. Breast Cancer Res 6:R629–R635. doi:10.1186/bcr933 PubMedCrossRef

12.

Jekimovs CR, Chen X, Arnold J et al (2005) Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals. Br J Cancer 92:784–790. doi:10.1038/sj.bjc.6602381 PubMedCrossRef

13.

Karhu R, Laurila E, Kallioniemi A, Syrjakoski K (2006) Large genomic BRCA2 rearrangements and male breast cancer. Cancer Detect Prev 30:530–534. doi:10.1016/j.cdp.2006.10.002 PubMedCrossRef

14.

Neuhausen S, Dunning A, Steele L et al (2004) Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer 108:477–478. doi:10.1002/ijc.11385 PubMedCrossRef

15.

Offit K, Pierce H, Kirchhoff T et al (2003) Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet 4:1. doi:10.1186/1471-2350-4-1 PubMedCrossRef

16.

Ohayon T, Gal I, Baruch RG, Szabo C, Friedman E (2004) CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 108:479–480. doi:10.1002/ijc.11603 PubMedCrossRef

17.

Sodha N, Wilson C, Bullock SL, Phillimore H, Houlston RS, Eeles RA (2004) Analysis of familial male breast cancer for germline mutations in CHEK2. Cancer Lett 215:187–189. doi:10.1016/j.canlet.2004.07.002 PubMedCrossRef

18.

Syrjakoski K, Kuukasjarvi T, Auvinen A, Kallioniemi OP (2004) CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer 108:475–476. doi:10.1002/ijc.11384 PubMedCrossRef

19.

Meijers-Heijboer H, Wijnen J, Vasen H et al (2003) The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 72:1308–1314. doi:10.1086/375121 PubMedCrossRef

20.

Wasielewski M, Vasen H, Wijnen J et al (2008) CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer. Clin Cancer Res 14:4989–4994. doi:10.1158/1078-0432.CCR-08-0389 PubMedCrossRef

21.

Meijer-van Gelder ME, Look MP, Bolt-de Vries J, Peters HA, Klijn JG, Foekens JA (2001) Clinical relevance of biologic factors in male breast cancer. Breast Cancer Res Treat 68:249–260. doi:10.1023/A:1012221921416 PubMedCrossRef

22.

Easton DF, Pooley KA, Dunning AM et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087–1093. doi:10.1038/nature05887 PubMedCrossRef

23.

James JJ, Evans AJ, Pinder SE et al (2003) Bone metastases from breast carcinoma: histopathological–radiological correlations and prognostic features. Br J Cancer 89:660–665. doi:10.1038/sj.bjc.6601198 PubMedCrossRef

24.

Smid M, Wang Y, Klijn JG et al (2006) Genes associated with breast cancer metastatic to bone. J Clin Oncol 24:2261–2267. doi:10.1200/JCO.2005.03.8802 PubMedCrossRef

25.

Kilpivaara O, Laiho P, Aaltonen LA, Nevanlinna H (2003) CHEK2 1100delC and colorectal cancer. J Med Genet 40:e110. doi:10.1136/jmg.40.10.e110 PubMedCrossRef

Title: CHEK2 1100delC and male breast cancer in the Netherlands
Authors: Marijke Wasielewski
Michael A. den Bakker
Ans van den Ouweland
Marion E. Meijer-van Gelder
Henk Portengen
Jan G. M. Klijn
Hanne Meijers-Heijboer
John A. Foekens
Mieke Schutte
Publication date: 01-07-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0162-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer

Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity

Acupuncture for the treatment of hot flashes in breast cancer patients, a randomized, controlled trial

Immortalization and transformation of human mammary epithelial cells by a tumor-derived Myc mutant

Three-dimensional pathological size assessment in primary breast carcinoma

The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer